The shadow
net asset value per share shown below does not
reflect the application of the amortized cost method of
valuing fund portfolio holdings, which normally allows the fund to maintain an official NAV of $ 1.00
per share.
* The Board believes that the offer price of $ 1.20
per share is approximately the company's current
net cash
value less wind down costs, but does not
reflect the
value for the company's other
assets, including its AV411 pain and addiction program and rights to future payments from Genzyme Corporation.